Nav: Home

Hydroxyurea improves lung function in children with sickle cell disease

May 18, 2016

ATS 2016, SAN FRANCISCO - For the first time, researchers were able to demonstrate that children diagnosed with sickle cell disease showed improvement in lung function after treatment with hydroxyurea, a treatment that is underused despite its demonstrated benefits. The study was presented at the ATS 2016 International Conference.

With 1 in 500 people affected, sickle cell disease is the most commonly inherited genetic disorder in people of African descent. "Persons with sickle cell disease experience an annual decline in lung function that starts in childhood," said Anya McLaren, MD, FRCP, MSc, lead author and respiratory medicine fellow at The Hospital for Sick Children in Toronto, Canada. "This study is the first of its kind to look at the effect of hydroxyurea on lung function. We found that hydroxyurea improves annual pulmonary function decline in children with sickle cell disease by more than one-third."

After receiving the treatment, all 94 study participants age 6 to 20 years old were followed for four years and their blood count, hemoglobin F, liver and renal functions measured at certain time points beginning at three months. Two measures of lung function - FEV1, which measures how quickly a person can move air out of his/her lungs, and FEF25-75, which helps determine if there is an obstruction in the airway - were taken before and after hydroxyurea. There was significant improvement in both FEV1 and FEF25-75 after treatment.

More than a decade of research in young people has produced data on the safety and effectiveness of hydroxyurea. Despite the evidence, Dr. McLaren believes clinicians' concerns about patient non-compliance and fears of potential side effects, namely carcinogenesis, are the primary reasons hydroxyurea is underused. But some of those fears may be unfounded.

"Long-term observational studies suggest beneficial effects without excessive damage to bone marrow, deleterious effects on growth and development, altered fertility, accumulation of mutations or increased carcinogenicity," said Dr. McLaren.

"Evidence that lung function may be better preserved while on hydroxyurea may encourage compliance and adherence to this medication for patients with sickle cell disease," added Dr. McLaren. "In combination with the established safety data, it hopefully will promote physician recommendations for hydroxyurea initiation and encouragement of compliance."
-end-
Abstract 6146

Effect of Hydroxyurea on Pulmonary Function Decline in Children with Sickle Cell Disease

A. McLaren1, M. Klingel2, S. Behera3, M. Kirby-Allen3, I. Odame4, H. Grasemann1

1Division of Respiratory Medicine, Hospital for Sick Children - Toronto, ON/CA, 2Program in Physiology and Experimental Medicine, Research Institute, Hospital for Sick Children - Toronto, ON/CA, 3Division of Hematology/Oncology, Hospital for Sick Children - Toronto, ON/CA, 4Div of Haematology/Oncology, Hospital for Sick Children - Toronto, ON/CA

Abstract Body

Introduction


Sickle cell disease (SCD) is one of the most common inherited blood disorders, affecting 1 in 600 African Americans. Pulmonary complications are the leading cause of morbidity and mortality in adults with SCD and a low FEV1 is predictive of earlier death. Hydroxyurea (HU) is known to decrease the number of acute sickle-related events such as pain and acute chest crises (ACS). We hypothesize that hydroxyurea (HU) therapy prevents the expected annual decline in pulmonary function in children with SCD.

Methods

Research Ethics Board approval was obtained for this project. Study participants were initiated on HU as decided by the treating hematologist. Participants were followed clinically over a 4-year period at 3, 6, 9, 12, 24, 36 and 48-month time points after HU initiation in Sickle Cell Clinic. Laboratory measurements (complete blood count, hemoglobin F, liver and renal function tests) were monitored at each of these time points. Pulmonary function tests (PFT) were collected up to median of 3.68 years pre and 3.84 years post initiation of HU. Percent predicted values were calculated using the NHANES reference equations. Linear regression analysis using generalized estimating equations to account for repeated measures were used to assess how outcomes differed with the use of HU after adjusting for time and other relevant covariables.

Results

PFT measurements were analyzed in 94 children between the ages of 6 and 20 years. The average age of HU start was 11.0 (+/-4.4) years. 96% had HbSS genotype and 47% were male. There was a greater than 1-fold increase in measured hemoglobin F each year of therapy. The annual rate of decline in predicted FEV1 and FEF25-75 before HU initiation was -1.98%/year (95% CI -2.57, -1.39) and -3.59%/year (95% CI -4.43, -2.75), respectively. After HU initiation, there was a significant (p<0.05) improvement in the annual decline of these two parameters to -1.28%/year (95% CI -1.79, -0.76) and -2.88%/year (95% CI -3.49, -2.28), respectively. Changes in FEV1 and FEF25-75 were independent of the age at and time from HU therapy initiation. There was no significant change in TLC, FVC or FEV1/FVC predicted measurements after HU initiation.

Conclusion

Hydroxyurea therapy in children with sickle cell disease results in improvement in pulmonary function decline over time. Not only do these findings support the use of hydroxyurea in children with SCD but may provide some insight into the pathophysiology of solid organ manifestation i.e. lung disease in SCD.

Session: D50 Pediatric Rare Lung Diseases
Wednesday, May 18, 2016, 9 a.m.
Location: Area E, Hall D (North Building, Lower Level), MOSCONE CENTER

American Thoracic Society

Related Lung Function Articles:

Inhaled immunosuppressant may increase survival, pulmonary function after lung transplant
University of Maryland School of Medicine researchers found that lung transplant recipients who had early signs of organ rejection could increase their chances of survival by inhaling a liposomal form of the immunosuppression drug cyclosporine through an investigational nebulizer.
Exposure to BPA in the womb linked to wheezing and poorer lung function in children
Pregnant women exposed to higher levels of the commonly used chemical bisphenol A (BPA) are more likely to have children who suffer with wheezing and poorer lung function, according to research presented at the European Respiratory Society International Congress.
Exposure to outdoor air pollutants, change in emphysema, lung function
Whether exposure to outdoor air pollutants is associated with emphysema progression and change in lung function was the focus of this observational study.
Girls who are more physically active in childhood may have better lung function in adolescence
A study of more than 2,300 adolescents underscores the pulmonary health benefits of physical activity.
Exposure to chemicals before and after birth is associated with a decrease in lung function
A European study, published in The Lancet Planetary Health, analyses for the first time the impact of the exposome on respiratory health.
Common e-cigarette chemical flavorings may impair lung function
Two chemicals widely used to flavor electronic cigarettes may be impairing the function of cilia in the human airway, according to a new study led by Harvard T.H.
Monitoring lung function at home in teens with Duchenne muscular dystrophy
Heart and lung complications are responsible for much of the morbidity and mortality associated with Duchenne muscular dystrophy (DMD).
E-cigarette additives increase inflammation and impair lung function, study finds
Flavoring and additive ingredients in e-cigarettes may increase inflammation and impair lung function, according to new research.
Exposure to organochlorine pesticides in the womb linked to poorer lung function in childhood
Babies exposed to higher levels of organochlorine compounds in the womb go on to have worse lung function in childhood, according to new research presented today (Tuesday) at the European Respiratory Society International Congress.
Flavonoids may slow lung function decline due to aging
A type of flavonoid found in dark-pigmented fruits like red grapes and blueberries may slow the lung function decline that occurs with aging, according to new research presented at the ATS 2018 International Conference.
More Lung Function News and Lung Function Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Accessing Better Health
Essential health care is a right, not a privilege ... or is it? This hour, TED speakers explore how we can give everyone access to a healthier way of life, despite who you are or where you live. Guests include physician Raj Panjabi, former NYC health commissioner Mary Bassett, researcher Michael Hendryx, and neuroscientist Rachel Wurzman.
Now Playing: Science for the People

#543 Give a Nerd a Gift
Yup, you guessed it... it's Science for the People's annual holiday episode that helps you figure out what sciency books and gifts to get that special nerd on your list. Or maybe you're looking to build up your reading list for the holiday break and a geeky Christmas sweater to wear to an upcoming party. Returning are pop-science power-readers John Dupuis and Joanne Manaster to dish on the best science books they read this past year. And Rachelle Saunders and Bethany Brookshire squee in delight over some truly delightful science-themed non-book objects for those whose bookshelves are already full. Since...
Now Playing: Radiolab

An Announcement from Radiolab